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This paper reflects on some of the ethical dilemmas that social workers face when assessing 
risk in relation to those using substances. It explores how legislation and societal factors can 
impact not just on people’s choices and decisions but also on their ‘vulnerability’ and access 
to services. Vulnerability, a contested term, is linked, in this paper, to assessment of risk. 
There are ethical issues that arise when assessing risk with people who use Anabolic 
Androgenic Steroid (AAS) from both service user and professional perspectives. These 
ethical issues concern a person’s right to choose and make potentially harmful decisions. The 
paper argues that using a substance such as AAS in and of itself does not suffice to make a 
person vulnerable but that this does not mean that people using AAS are not in need of 
support. It suggests that there may be some groups of people who are more at risk to starting 
AAS use and that social workers should be aware of these. It also recommends the need for 
further qualitative research to understand the reasons for starting use and support to help 
people stop using AAS. 
Keywords Anabolic Androgenic Steroids (AAS); Image and Performance Enhancing Drugs 
(IPED); social work; substance use; ethics; vulnerability; body image; media; legislation; risk 
1. Introduction 
In recent years, there has been an increase in Anabolic Androgenic Steroid (AAS) use in the 
UK and it is estimated that 61, 000 people in the UK used AAS in 2016/2017 (Webb 2017). 
However, these statistics are from the UK National Crime Survey statistics, and it is 
recognised that usage may be under-reported (Advisory Council on the Misuse of Drugs 
(ACMD) 2010). AAS are categorised as Image and Performance Enhancing Drugs (IPEDs) 
and can be taken both orally or by intra-muscular injection. There has been an increase in 
people who use AAS accessing Needle and Syringe Programmes (NSPs) (McVeigh and 
Begley 2016) and these have become an established part of the services provided for AAS 
users (Kimergård and McVeigh 2014). The provision of these services remains aligned to the 
needs of more traditional services users, such as people with opiate dependency, and provide 
an anonymous needle exchange and harm minimisation service and access to group or one-
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to-one support. My initial view, based on my time as a student social worker in a substance 
misuse team, presumed that the people who use AAS, like other substance using clients 
would be vulnerable, due to the risks around using non-prescribed substances. Support 
services, such as these, offer equity of support; however, this assumes a level of homogeneity 
around the risks, and services for different types of substance users. This is possibly because 
more traditional clients use illicit drugs that can affect their daily living; however, this is not 
necessarily true for people who use AAS. A more detailed exploration of the issues revised 
my opinion, highlighting that the concept of risk around AAS use is complex and raised 
ethical considerations linked to wider implications to social work practice. Therefore, in this 
paper I will consider AAS use in relation to social work and vulnerability, risk, harms, ethics, 
and legislation. 
2. From Vulnerability to Risk 
The Government’s Drug Strategy (UK Home Office 2017) highlighted that the use of IPEDs 
was a cause for concern particularly related to the associated risks to health. The focus of the 
Strategy was on preventing people from starting drug use, restricting the availability of drugs, 
and offering people with drug dependency problems, recovery and support, with a particular 
emphasis on protecting vulnerable children and adults (UK Home Office 2017). The strategy 
has people who misuse substances as an example of vulnerable people but gives no definition 
for the term vulnerable. This is potentially concerning as it assumes that all those who misuse 
substances are the same and the use of the term vulnerable could be seen as oppressive as it 
can attribute a ‘victim status’ (Parker et al. 2012). This may go some way to explain why 
Services provide similar support to all regardless of the substance used. However, this may be 
an unfitting status for people who use AAS, as they often are dedicated to maintaining a 
healthy lifestyle (Zahnow et al. 2018) and choose to use AAS as part of this. 
Any individual could be seen as potentially vulnerable (Parker et al. 2012) and as the Drugs 
Strategy does refer to vulnerable people it is worth reflecting on this concept. One starting 
point to determine if a group of users might be vulnerable is to consider the definitions of 
vulnerability within the literature and legislation. The nature of vulnerability has been defined 
in different ways, and distinctions made between active experience compared to the risks and 
harm that a particular demographic group are susceptible to (Greenfields, Fanning, and 
Dalrymple 2012), and this is played out in UK legislation. The Protection of Freedoms Act 
2012 states that a ‘vulnerable adult’ is a person (aged eighteen or over) who is subject to 
regulated activity. This definition would not necessarily apply to people who use AAS. Some 
AAS users access support from NSPs and it could be argued this is a regulated activity. 
However, NSPs are part of a harm reduction strategy (Bates, Jones, and Mcveigh 2013), and 
users of these services visit voluntarily, don’t have allocated workers, and retain their 
anonymity. Therefore, using such a service to obtain needles could suggest an ability to care 
for oneself and attendance could indicate a clear intention to protect themselves from harm. 
This could arguably be true of all those who are accessing the service. 
The Care Act 2014 does not refer to vulnerability but instead to adults ‘at risk’. This is a 
potentially more useful term to encapsulate the varied definitions of vulnerability 
(Greenfields, Fanning, and Dalrymple 2012), as using substances doesn’t automatically imply 
harm, merely risk (Heanue and Lawton 2012), and ethical practice asks social workers to 
enable people to identify and manage risks to themselves and others (Galvani 2012). The 
shift to the term ‘at risk’ in recent UK legislation could be seen as helpful as it allows social 
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workers to assess risk and balance potential harms against perceived or actual benefits. To 
remove the concept of vulnerability from the legislation but to use the term ‘most vulnerable’ 
in a Government Strategy document that is intended to inform those in professional practice 
to support people, is potentially unhelpful and even confusing. It might be more useful, at 
least for the purposes of consistency and assessment, to use the term ‘at risk’. It is also 
unhelpful to include people who use IPEDs in the same Drugs Strategy as those who use 
illegal substances such as heroin, as the potential harms from use are different and AAS users 
are often wary of accessing such services for fear of being labelled as ‘junkies’ (Simmonds 
and Coomber 2009). 
With the aforementioned increase in AAS use in the UK, there is the potential that even 
social workers, working outside of substance use services, will come across people who use 
AAS, particularly those working with young people and families. Therefore, it is useful to 
review the types of harm associated with AAS use and consider if these would lead to a 
potential increase in risk to the individual or risk to others. Additionally, wider engagement 
with stakeholders, including social workers, around the issues of using AAS could help to 
minimise harm (Evans-Brown et al. 2012). 
3. Harms Associated with Using AAS 
The lifetime prevalence of AAS has been estimated at 3.3% globally, with higher prevalence 
among males (6.4%) (Sagoe et al. 2014) and, users often use supra-physiological doses 
(Parkinson and Evans 2006). AAS use is linked with a wide range of potential negative 
physical harms including: erectile dysfunction, testicular atrophy, liver toxicity, dermal 
scarring, cognitive problems, gynaecomastia, muscle damage, myocardial injuries, and 
infertility (Nieschlag and Vorona 2015). Although, these physical harms are unpleasant and 
could have a significant impact on health they in and of themselves do not necessarily make a 
person vulnerable but do come with a certain amount of risk. There are also risks from 
injecting use such as contracting Blood Borne Viruses (BBVs) e.g., Hep C/HiV (Rowe et al. 
2017; Pope et al. 2014). Moreover, there are potential psychological effects of use including 
depression, aggressive tendencies, and anxiety (Barceloux and Palmer 2013; Piacentino et al. 
2015; Griffiths et al. 2016). Further risks include the risk of physical and psychological harm 
from using AAS in combination with illicit substances and/or other IPEDs (Sagoe et al. 2015; 
Beaver et al. 2008) and risks from self-medication of side-effects (Skårberg et al. 2007). It is 
noteworthy that people who use AAS will experience these risks to different degrees, and 
many take time to research the different substances (Christiansen, Vinther, and Liokaftos 
2016) and mitigate for side effects. Moreover, people take different approaches to risk 
management, e.g., one study found only 22% of AAS users accessed BBV tests (Hope et al. 
2015) despite the risks and another found that 67% of AAS users did not visit a doctor 
despite being worried about the negative side effects, as they did not think it serious enough 
(Zahnow et al. 2017). 
When assessing risk, consideration should also be given to potential harm to others and in the 
largest study (to date) of 1,955 US AAS users, the typical user was 30 years of age, white, 
male and in employment (Cohen et al. 2007). However, some studies from the UK and US 
have shown the onset of use before the age of 18 (Bates and McVeigh 2016; Hildebrandt 
et al. 2014). With AAS use, harms to others could include harm from an increase in 
aggressive behaviours (van Amsterdam, Opperhuizen, and Hartgens 2010), from the 
spreading of BBVs (Rowe et al. 2017) or to children from storing substances and needles in 
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the home (Nutt 2012). Despite the fact that AAS use has been shown to impact on people’s 
mood (Piacentino et al. 2015), this author could find no causal evidence of people who have 
lost control whilst using AAS. However, there is significant qualitative evidence in the 
literature to suggest that AAS can cause people to feel irritated and angry whilst using certain 
types of AAS (Hanley Santos and Coomber 2017; Dunn 2015) and another study found that 
compared with non-AAS users, young adult male AAS users reported greater involvement in 
violent behaviours (Beaver et al. 2008). Social workers need to be aware that a change in 
mood is a risk from using AAS and could potentially affect an individual’s mental health 
and/or decision making. It is difficult to find causal links for the use of AAS as users tend to 
take a mixture of drugs, to enhance their body and mitigate side effects and there could be 
other comorbidities. Therefore, more research into this area is needed to fully understand the 
effects of AAS use on mood and behavioural change. 
4. Risks to the Initiation of AAS Use 
If people choose to use AAS, then they are entitled to make that decision, as despite the 
potential risks of harm, AAS use in the UK is legal. Social workers have a duty to take 
preventative action, promote support and protection, yet also promote independence and 
balance rights and risks (The British Association of Social Workers (BASW) 2017). 
Therefore, consideration should be given to those more at risk of starting use as AAS can 
have a detrimental impact on a person’s physical and psychological health. AAS use among 
16 to 24 year olds has increased from 0.1% in 2015/2016 to 0.4% in 2016/2017 (Webb 2017) 
and there is a risk with adolescent use of AAS of an increase in neurological disorder or 
development of maladaptive behaviours (Cunningham, Lumia, and McGinnis 2013). Poverty, 
abuse, and a range of childhood problems have been overly represented in AAS users 
including poor relationship with parents, history of mental or physical abuse and problems at 
school (Wichstrom and Pedersen 2001; Skårberg et al. 2007). Many UK social workers are 
likely to come into contact with young people with such histories in their work and a US 
meta survey found that 22% of users started use before the age of 20 (Pope et al. 2013). 
People trans-gendering from female to male (Onakomaiya and Henderson 2016) and people 
who are gay (Copeland, Peters, and Dillon 2000; Iversen, Hope, and McVeigh 2016) are at 
risk of initiating use and one study found evidence that some ‘recovering’ heroin users turn to 
AAS as a quick fix to look healthy (Cornford, Kean, and Nash 2014). Social pressure in the 
form of media influence, peer influence, and sport or social norms also emerged as an 
important driver for the initiation of AAS use (Sagoe, Andreassen, and Pallesen 2014). 
Additionally, some vocations including doormen, soldiers, police and models, have been 
found to be motivations to start using AAS (Fogel and Vogel 2012). For social work 
professionals wanting to understand the differing motivations, it may be of use to explore the 
typologies of AAS users (Zahnow et al. 2018) that have been recently presented in the 
literature. 
There is an argument to suggest that government guidance could expose young people to 
environments where AAS is used, as the NHS encourages the promotion of regular exercise 
for young people (National Institute for Health and Clinical Excellence 2009). Hollingworth 
(2012) advocates that social care professionals should make these activities a priority. 
However, the UK Guidance on provision of services for people who use IPEDs suggests that 
outreach support should be undertaken in gyms (Public Health England 2014) as studies 
yielding the highest prevalence rates for AAS injection have used gym and fitness centre 
settings (Sagoe, Andreassen, and Pallesen 2014). There is a need to take into consideration 
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that those young people who may be seeking to undertake these activities might do so 
because they have underlying issues about their body identity. Adolescents with poor self-
image or conduct problems (J. H. Pope, Kanayama, and Hudson 2012), people concerned 
about body image, those with low self-esteem and low self-efficacy, and those with muscle 
dysmorphia or eating disorders, (Rohman 2009; Jenssen and Johannessen 2015; Sagoe, 
Andreassen, and Pallesen 2014; Walker and Eli Joubert 2011) are all at risk of initiating use. 
Moreover, the odds of lifetime AAS use were found to be 1.4 times higher for those 
adolescents who exercised almost daily (Kokkevi et al. 2008). 
Social workers incorporating fitness into support plans should consider the risks and be aware 
that young people may encounter people who use AAS in gym environments who could be 
seen as ‘desirable’ role models as they appear muscular and confident. It is widely 
acknowledged that body shape and physical control are central to a person’s sense of identity 
(Coffey 2016) and adolescent development is said to be connected to a search for identity 
(Erikson and Erikson 1997) and gender role (O’Neil 2015). It is suggested that the use of 
AAS for aesthetic gain is ‘indicative of the public’s appetite for a short cut’ (Brennan, Claire 
Van Hout, and Wells 2013), and the increase in use may simply be a by-product of this or 
because of the availability of AAS online. However, consideration should also be given to the 
need to define their masculine identity. A young man’s desire to have the perfect masculine 
body is fuelled by the proliferation of the mesomorphic body shape in the media (Daniel and 
Bridges 2010). Moreover, internalisation of body ideals mediated the relationship between 
masculine role norms and body image in the drive for muscularity (De Jesus et al. 2015) and 
body image concern is a risk factor for AAS use (Kanayama et al. 2006; Jenssen and 
Johannessen 2015). Arguably, this body ideal is not just targeted at young men, increasingly 
media representations of middle-age celebrities focus on a muscular physique, and the 2015 
UK survey on IPEDs found that a number of participants started use after the age of 40 
(Bates and McVeigh 2016). However, the majority of AAS users in the UK 2015 survey 
initiated use between the ages of 20 and 25 years old (Bates and McVeigh 2016). Could the 
initiation age of early twenties align to the idea that men can develop a negative self-image 
due to media pressure and that ‘the relationship becomes stronger into early adulthood’ 
(Barlett, Vowels, and Saucier 2008, 295). This speaks to wider societal and ethical 
perspectives as marketing and media industries promote an image of an ideal male form 
which is muscular. The representation of male body image in society has changed in recent 
years as exemplified by Action Man and other toys aimed at boys which have increased their 
musculature (Pope, Khalsa, and Bhasin 2017). This unrealistic body image is also often found 
in mainstream reality television programmes (Dallesasse and Kluck 2013). It is not just boys 
who could be influenced, as girls’ ideas of the ideal boyfriend could also be influenced, for 
example to attain the same body proportion’s as Barbie’s Ken, an average young man would 
need to increase his chest by eleven inches (Brownell and Napolitano 1995). The media is 
full of pictures of ‘ripped’ men many of whom have been photo-shopped and such images 
can have a negative impact on how men see themselves (Blond 2008). 
This body ideal is further emphasized through social media and the popularity and idolisation 
of young people who use AAS e.g., Zyzz, now deceased, still has millions of followers on his 
webpages. He stated one of his reasons for choosing to body-build (and there is online 
evidence of him using AAS) was about image: 
I had a girlfriend of 17, who was pretty but slightly chubby, when I was a skinny nerd, she 
kept pointing out how skinny I was & always looked at other guys with good bodies which 
was one of the reasons I wanted to start going to the gym. Needless to say when I saw her 2 
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years later her jaw dropped, brushing her off at that moment was probably the best feeling I 
have experienced in my life [text in Zyzz transformation progress video] (Underwood 2017) 
Or, Jon Skywalker, who self-promotes his change in physical appearance from AAS use and 
has a personal motto of ‘lifes too short to be unaesthetic (sic)’ (Skywalker 2017). Studies 
have shown that men choose an ideal body that is more muscular than themselves and 
estimate that women prefer a more muscular male body (Pope et al. 2000) and the media does 
influence the drive for muscularity (Cramblitt and Pritchard 2013; De Jesus et al. 2015; Melki 
et al. 2015). Retailers and the media promote various ideal body images whilst taking no 
responsibility for the negative impact they have on their audience. It seems ironic that for 
years people have acknowledged the damage caused by the proliferation of idealised images 
of women’s bodies to females’ self-esteem yet now society is putting men in a similar 
position. 
In assessing risk around substance use, people who are diagnosed with substance dependence 
could be considered at greatest risk of harm as people can feel they do not have any other 
options other than to continue using the substances despite any harmful consequences. The 
ICD-10 (World Health Organisation 2010) lists AAS as non-dependence producing 
substances whereas the DSM-5 (American Psychiatric Association 2013) categorises AAS 
under other substances but does not explicitly state non-dependent and instead has criteria for 
substance use disorders (e.g., mild anabolic steroid use disorder). Although social workers do 
not diagnose dependency, it is important that they have an understanding that there has been a 
case put forward for AAS dependency in order to be able to make an appropriate risk 
assessment. Kanayama et al.’s (2009) analysis concluded on the basis of seven studies that 
30% of AAS users develop dependence based on DSM-IV criteria and therefore it is a valid 
diagnostic entity. Kanayama and Pope (2016) suggest that one route to AAS use is via its 
potentially hedonic properties, in that AAS users often say that using AAS gives them a sense 
of ’invincibility’ (Pope et al. 2014). The other two routes to dependency suggested relate to 
the neuroendocrine effects and body image concerns (Kanayama and Pope 2016). The DSM-
5 saw the introduction of Muscle Dysmorphia as a defined type of body dysmorphia 
(Kanayama and Pope 2016; American Psychiatric Association 2013) and cites AAS use a 
potential risk with this condition. 
Potentially, therefore, the risks of using AAS can change over time. Psychological side 
effects can increase with severity of use (Pagonis et al. 2006) as can the likelihood of 
developing more harmful physical side effects such as cardiovascular toxicity (Kanayama, 
Hudson, and Pope 2008). Moreover, one way to overcome the feelings of depression that 
some users experience at the end of a cycle (Griffiths et al. 2016) would be to start a new 
cycle or use a low dose continuously. It could be that the longer people use AAS, the more 
likely it is that they could be at risk of developing a dependency. Rogers (2013) argues that as 
well as psychological and physical harms, dependent use may increase their likelihood of 
being targeted by unscrupulous dealers, as the nature of the use has changed from voluntary 
to involuntary. Although, it could be argued that even with dependent use, people make 
choices around that use. However, their choice to continue to use rather than seek support 
may be because they are not aware of other options available to them, that the benefits of use 
outweigh the negative effects for them or because of a lack of experience or support. 
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5. The Legal Situation 
One aspect of risk is that of potential exploitation. In the UK, the legislation on AAS 
contributes to wider societal ethical dilemmas as AAS are classified as Class C substances 
and although it is legal to use it is illegal to supply it (Misuse of Drugs Act, 1971). In 2012, 
changes in the law made it illegal to import steroids by ordering them online and having them 
delivered to you from outside the UK. Consequently, people seeking to import them from 
overseas have to bring them in person. However, regardless of the legality it is easy to buy 
steroids online and many of the sites that offer advice on use also advertise the products. 
Thiroux and Krasemann (2014) ask if people should use laws and rules as the basis for their 
choices. If so, then the legality for personal use in the UK could be seen as justification to 
use, yet creates a dilemma for them as obtaining AAS may necessitate users breaking the law 
as it is potentially prohibitively expensive to keep travelling overseas to purchase the drugs. 
For people in professions, such as law enforcement or the military, who choose to use AAS, 
the issue around legality is especially challenging. For example, the police are deemed an at 
risk profession for AAS use (Hildebrandt et al. 2007; Fogel and Vogel 2012) and the UK’s 
police work under a code of conduct with an obligation not to misuse legal substances 
(College of Policing 2014). This then puts them at the potential risk of reprisal for their 
actions. However, it also asks the question, how do you determine misuse? AAS use is legal, 
and potentially therefore misuse would come from supplying AAS but not personal use. Yet, 
one press report highlights a case of a police officer who thought that he was not breaching 
regulations and was sacked for misconduct for personal steroid use (Evening Chronicle, 
2011). 
Current UK law has the potential to put people at risk as it forces licit users of AAS to engage 
in criminal networks to purchase substances while having no legal recourse and no consumer 
rights. Moreover, this could place them at risk by forcing them into an unregulated black 
market, and illicitly purchased products can be of variable strength (Nutt 2012), adulterated 
(Van Hout and Kean 2015) or counterfeit (Cho et al. 2015; Coomber et al. 2014). Much of 
the harm of drug use is linked with stigmatisation and criminalisation, and society should be 
responsive to vulnerability and strive to promote autonomy (Ben-Ishai 2012). In one sense, 
the current legal situation does allow people to exercise autonomy. By permitting personal 
use, people who use AAS are not criminalised in the same way as those who use illicit 
substances. If AAS use was illegal, this might increase risks by potentially increasing the 
stigma and stopping people from accessing services. However, the current law, legislation 
and policy surrounding AAS use sends mixed messages both to people who use and those 
who support them. It is important for social workers to be aware of the confusion and 
stigmatisation that this can create for people who use AAS, and it may be why AAS users 
might distrust professionals and be reticent about disclosing their use. People who use AAS 
suggest that the risks of using AAS are akin to those of tobacco or alcohol (Walker and Eli 
Joubert 2011). Such products are legal to purchase however if alcohol was discovered today, 
Nutt et al. (2007) argue that it could be classified as a class A drug based on the forms of 
harm from use. Ethics deal with identifying rights and wrongs of human conduct, and should 
consider the part ‘self-interest or the interests of others play in making moral decisions and 
judgements’ (Thiroux and Krasemann 2014, 2). Does the fact that alcohol consumption is 
part of everyday life and brings in significant tax revenue, e.g., in 2009/2010 around 2% of 
the UK government’s total revenue from taxation (Collis, Grayson, and Johal 2010) influence 
the legislation? The current UK drugs legislation although intended to minimise risk could be 
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seen as unethical and unhelpful. Taylor et al. (2016) put forward that the social construction 
of drugs and drug users should be challenged, that a new approach is needed which is not 
about punishment and prohibition but instead focused on understanding people’s individual 
situations and motivations and AAS should be seen in this light. 
Caring professionals may base their moral judgements on using a Class C substance, which 
could lead to inequalities in access to services. In one study, a participant explained that his 
doctor had no time for him, and expressed his frustration that the doctor would have done had 
he been seeking help for the consequences of smoking or drinking (Walker and Eli Joubert 
2011). This distrust of medical professionals by people who use AAS is found across a large 
range of studies (Grogan et al. 2006; Zahnow et al. 2017; Cohen et al. 2007; Maycock and 
Howat 2005). The implication being that carrying out activities that cause harm, but are 
socially acceptable and possibly engaged in by the professional themselves, allows access to 
services. However, engaging in drug-related activities that people believe to be ‘wrong’ is 
more likely to result in discrimination, possible exclusion and leave people at risk of having 
to find alternative options which are often more risky e.g., self-treating (Hope et al. 2015; 
Skårberg et al. 2007). People who choose to use AAS are stigmatised by the press and public, 
possibly influenced by media stories of ‘roid rage’ (Griffiths, Murray, and Mond 2016; 
Maycock and Howat 2005), and can feel stigmatised by medical professionals (Yu, 
Hildebrandt, and Lanzieri 2015). Some people who use AAS want professional medical 
support (Pates and Barry 1996; Cohen et al. 2007) and many do not trust their doctor to tell 
them they use AAS (Grogan et al. 2006; Cohen et al. 2007; Parkinson and Evans 2006). 
Such judgements by professionals serve to reinforce stigma, however, the professionals 
themselves are faced with ethical dilemmas concerning use that could cause harm. However, 
with social work practice having at its heart values such as acceptance, self-determination of 
the service user and non-judgementalism, hopefully AAS users would not experience such 
stigma when working with social work practitioners. 
6. Potential Ethical Issues for Social 
Workers 
An ability and commitment to act ethically is a key part of the services social workers offer 
(British Association of Social Workers Policy Ethics and Human Rights Committee 2012). 
Central to any ethical decision-making process are one’s own values (Dolgoff, Harrington, 
and Loewenberg 2005), and social workers are encouraged to reflect on their values when 
dealing with substance use (Galvani 2015). 
Prior to working directly in a substance use service, my understanding of AAS was limited to 
lay knowledge mainly influenced by media representations e.g., Arnold Schwarzenegger and 
the concept of ‘roid rage’. This could be true of other professionals as we are influenced by 
our culture and the predominant media portrayal of people who use AAS is negative 
(Griffiths, Murray, and Mond 2016). 
Social workers often face ethical dilemmas when having to balance confidentiality against the 
duty to protect others (Reamer 2013). For example, if a partner has confided their use to a 
social worker, but has kept this secret from his family, does the social worker have the right 
to disclose when considering risk? For example, if, the AAS user has a partner and children is 
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a risk to the children from the storage of needles at home? How does the social worker’s own 
understanding of AAS use impact on their decision-making? The risks of harm to others 
based on the available evidence are not conclusive, and it could be a breach of confidentiality 
to disclose. Moreover, AAS use is legal for personal use in the UK. On the other hand, the 
potential to put others at risk should not be ignored, and as such should be included in the risk 
assessment, with the intent, if possible, to discuss the particular risks with the person who is 
using AAS. Moreover, as relation-based practice is present within social work practice 
(Trevithick 2012), the risk assessment could be the starting point for a discussion and open 
the potential for social workers to support their clients to reflect on their choices. 
The proliferation of muscular stereotypes in the media could have ethical implications. 
Arguably, the UK Government has a responsibility to address such matters through 
regulation e.g., banning the proliferation of photo-shopped ‘unrealistic’ images. However, 
this comes with its own challenges relating to the question of personal freedoms. Particularly, 
when working with adolescents, social workers could face an ethical dilemma in that what 
they may consider to be sensible choices for the client could differ from what the client 
believes is beneficial (Dolgoff, Harrington, and Loewenberg 2005). For example, a service 
user could argue that using AAS decreases their risk of being harmed by others and increases 
their confidence (Vassallo and Olrich 2010) and may be unaware of or unconcerned about the 
potential side effects, for example ‘I felt I was skinny & got bullied…it makes me feel good 
& strong’ (Walker and Eli Joubert 2011). They may see the positive gains outweighing the 
negative problems and may not be considering long term plans such a starting a family, and 
as such may give lower weight to such potential side effects as infertility, yet this could have 
serious implications for their future. According to Kant, an unconditional right is for a person 
to determine their own destiny (Dolgoff, Harrington, and Loewenberg 2005) and this is 
enshrined in UK law as people have the right to make unwise choices (Mental Capacity Act, 
2005). This could prove challenging for a professional as, if using AAS improves a person’s 
self-confidence and they believe it gives them a better quality of life, then that is their 
decision. Yet the ACMD (2010) expresses particular concerns for the potential negative 
impact of AAS use on the physiological and behavioural development of young people. As 
there is no guidance for supporting those who use AAS, social workers may face dilemmas in 
relation to managing risks presented by those who wish to enhance their physical appearance. 
An awareness of the societal pressures that might be influencing a young person’s decision 
making could be useful when having conversations with them about such topics as self-image 
and IPED use. 
One extreme example of where the media rhetoric could influence values and ultimately 
decisions relates to the Prevent agenda. Prevent is the UK Government led strategy on 
safeguarding people and communities from the threat of extremism and is one of the four 
elements of the Government’s counter-terrorism strategy (HM Government, 2011). There 
have been reports that people in Western countries use AAS in preparation for racially 
motivated atrocities e.g., Anders Breivik and Omar Mateen (Melle 2013; Wilber 2016) and 
more recently press reports in the case of Kalid Masood for the Westminster attacks (Slawson 
2018). In his manifesto, Breivik (2011) recommends the use of steroids for strength and 
improved physical performance. Controversially, under Prevent, professionals are asked to 
identify people vulnerable to radicalisation and identify the signs (HM Government 2011). 
Could a sudden decision to start using AAS be a sign of radicalisation? Should this be 
reported? When considering AAS use in such cases as extreme violence, evidence-based 
practice is problematic as the evidence is limited to one case study and several media stories 
that don’t provide robust academic evidence. However, it would be beneficial for social 
10 
 
workers to be aware of the range of motivations for use. It is clear that, in such complex 
scenarios, to maintain an ethical social work practice requires as complete a picture as 
possible, which could be gained from ‘rigorous assessment and respectful intervention’ 
(Stanley et al. 2015, 1). 
7. Conclusion 
In conclusion, the majority of people who use AAS are not vulnerable as a result of their use, 
even though they are potentially putting their own health at risk and these risks may increase 
should they become dependent on AAS. This is because they are not a proven risk to others, 
there is a low risk of overdose, AAS is legal for personal use, and there is no evidence that 
they are unable to manage daily living whilst using AAS. However, there may be a subgroup 
of people who are more at risk to starting use e.g., men who have been bullied, have low self-
esteem, pre-existing mental health conditions or poor body image perception. Often social 
workers will find themselves working with people from this subgroup and they need to be 
aware of the risks for starting AAS use but also acknowledge that just because there is an 
increased risk that does not necessarily mean that this is a fait accompli as there are multiple 
factors that influence the initiation of AAS use. Further qualitative research considering the 
reasons for starting use and support to help people stop using AAS would be beneficial. 
People who use AAS seem to be an almost invisible population of users who may benefit 
from specialised support. This exploration has raised questions around the vulnerability of 
AAS users, and the risks for starting use, as well as considering the ethics of how the media 
portrays masculinity, and the UK legal status of AAS. It is particularly concerning that 
society is subjecting men to unrealistic stereotypes for body image perfection that have long 
been a challenge for women, rather than seeking to celebrate the natural figure. In relation to 
social work practice, this discussion has highlighted the need for social workers to be aware 
that some of the people that they might be supporting might be more susceptible to initiating 
AAS use, or may be using AAS and unaware of the potential long-term harms. It would be 
helpful for social work practitioners to understand the motivations for AAS use so that they 
are able to have frank discussions about the associated risks. As with most social work 
dilemmas, when working with people, there are rarely fixed solutions, only individual 
situations, perspectives and a need to balance risk. 
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